At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses chemotherapy, kinase inhibitors and ongoing research in personalized approaches for the treatment of patients with chronic lymphocytic leukemia.

свернуть